|
Medically at risk
|
Healthy individuals
|
Occupationally at risk
|
Travellers
|
Who should be vaccinated?
|
Those with medical risk factors for invasive meningococcal disease, including:
- complement deficiencies
- current or future treatment with eculizumab
- haemoglobinopathies
- haematopoietic stem cell transplant
- functional/anatomical asplenia
- people living with HIV
|
Anyone aged ≥6 weeks who wishes to reduce their risk of invasive meningococcal disease, and in particular the following high-risk demographics:
- infants aged <2 years
- adolescents aged 15–19 years
- Aboriginal and Torres Strait Islander children aged <15 years
- adults aged 20–24 years who live in close quarters (e.g. military, student accommodation)
- adults aged 20–24 years who smoke
|
E.g. laboratory workers who handle Neisseria meningitidis
|
Travellers aged ≥6 weeks travelling to a country endemic for meningococcal A, C, W or Y, as well as Hajj pilgrims
|
Which vaccine(s) are recommended?
|
MenACWY
MenB
|
MenACWY MenB
|
MenACWY MenB
|
MenACWY
|
Which vaccine(s) are NIP funded?
|
Nil
|
National Immunisation Program: Nimenrix (MenACWY) is funded at 12 months (GP) and at School Year 10 (14–16 years, school-based program), with catch-up for 15–19 year olds who have not received a dose previously (GP based).
|
Nil
|
Nil
|
|
6 weeks – 5 months
|
6–8 months
|
9–11 months
|
12–23 months
|
≥2 years
|
6 weeks – 5 months
|
6–8 months
|
9–11 months
|
12–23 months
|
≥2 years
|
|
|
MenACWY
|
Further MenACWY booster doses required?
|
4 doses
Minimum 8-week intervals. 4th dose at 12 months of age or 8 weeks after 3rd dose, whichever is later
|
3 doses
Minimum 8-week intervals. 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later
|
3 doses
Minimum 8-week intervals. 3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later
|
2 doses
Minimum 8-week interval
|
2 doses
Minimum 8-week interval
|
3 doses
Minimum 8-week intervals
3rd dose at 12 months of age or 8 weeks after 2nd dose, whichever is later
|
2 doses
2nd dose at 12 months of age
|
2 doses
2nd dose at 12 months of age
|
Nimenrix: 1 dose
Menveo/Menactra: 2 doses, 8 weeks apart
|
One dose
|
Dosing depends on presence of medical risk factors or not
|
Dosing depends on presence of medical risk factors or not
|
Preferred brands (MenACWY)
|
Menveo or Nimenrix
(Menactra not registered for use for this age group)
|
Menveo, Nimenrix or Menactra*
|
Menveo or Nimenrix preferred to Menactra*
|
Menveo or Nimenrix
(Menactra not registered for use for this age group)
|
Menveo, Nimenrix or Menactra*
|
Menveo or Nimenrix preferred to Menactra*
|
Menveo or Nimenrix preferred to Menactra*
|
Menveo or Nimenrix preferred to Menactra*
|
Further MenACWY booster doses required?
|
Yes, if ongoing increased risk of invasive meningococcal disease
If age ≤6 when completed initial MenACWY vaccination course, give MenACWY booster 3 years after primary schedule, then every 5 years
If age ≥7 when completed course, give MenACWY booster every 5 years
|
No, not required
|
Yes, every 5 years
|
Yes, every 5 years if ongoing risk
|
|
6 weeks – 5 months
|
6–11 months
|
12 months – 9 years
|
≥10 years
|
6 weeks – 11 months
|
12 months–9 years
|
≥10 years
|
|
|
MenB
|
MenB dosing schedule by age at first dose
|
Bexsero: 4 doses, minimum 8-week intervals, 4th dose at 12 months or 8 weeks after 3rd dose, whichever is later
|
Bexsero: 3 doses, minimum 8-week intervals, 3rd dose at 12 months or 8 weeks after 2nd dose, whichever is later
|
Bexsero: 2 doses, minimum 8-week interval
|
Bexsero: 2 doses, minimum 8-week interval
Trumenba: 3 doses. Dose 2 should be ≥4 weeks after dose 1. Dose 3 ≥4 months after dose 2 and ≥6 months after dose 1
|
Bexsero: 3 doses
Minimum 8-week intervals, 3rd dose at 12 months or 8 weeks after 2nd dose, whichever is later
|
Bexsero: 2 doses
Minimum 8-week interval
|
Bexsero: 2 doses, minimum 8-week interval
Trumenba: 2 doses, minimum 6-month interval
|
Dosing depends on presence of medical risk factors or not
|
MenB is not routinely recommended for travellers
|